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We examined risk of second solid cancers after allogeneic hematopoietic cell transplantation (AHCT) using
reduced-intensity/nonmyeloablative conditioning (RIC/NMC). RIC/NMC recipients with leukemia/myelodys-
plastic syndrome (MDS) (n ¼ 2833) and lymphoma (n ¼ 1436) between 1995 and 2006 were included. In
addition, RIC/NMC recipients 40 to 60 years of age (n ¼ 2138) were compared with patients of the same age
receiving myeloablative conditioning (MAC, n ¼ 6428). The cumulative incidence of solid cancers was 3.35% atedgments on page 1783.
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Reduced-intensity conditioning
Nonmyeloablative conditioning
Second cancers
Solid tumors10 years. There was no increase in overall cancer risk compared with the general population (leukemia/MDS:
standardized incidence ratio [SIR] .99, P ¼ 1.00; lymphoma: SIR .92, P ¼ .75). However, risks were signiﬁcantly
increased in leukemia/MDS patients for cancers of lip (SIR 14.28), tonsil (SIR 8.66), oropharynx (SIR 46.70),
bone (SIR 23.53), soft tissue (SIR 12.92), and vulva (SIR 18.55) and skin melanoma (SIR 3.04). Lymphoma
patients had signiﬁcantly higher risks of oropharyngeal cancer (SIR 67.35) and skin melanoma (SIR 3.52).
Among RIC/NMC recipients, age>50 years was the only independent risk factor for solid cancers (hazard ratio
[HR] 3.02, P < .001). Among patients ages 40 to 60 years, when adjusted for other factors, there was no
difference in cancer risks between RIC/NMC and MAC in leukemia/MDS patients (HR .98, P ¼ .905). In lym-
phoma patients, risks were lower after RIC/NMC (HR .51, P ¼ .047). In conclusion, the overall risks of second
solid cancers in RIC/NMC recipients are similar to the general population, although there is an increased risk
of cancer at some sites. Studies with longer follow-up are needed to realize the complete risks of solid cancers
after RIC/NMC AHCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
It is well established that patients treated with allogeneic
hematopoietic cell transplantation (AHCT) using myeloa-
blative conditioning (MAC) are at increased lifelong risk for
second solid cancers [1-8]. A latency period of 3 to 5 years
occurs before second solid cancers start appearing after
AHCT, and most recent large studies have reported cumula-
tive incidence rates of 1% to 2% at 10 years and 3% to 5% at
20 years after transplantation. The incidence of solid malig-
nancies continues to rise with increasing survival after
transplantation, and lifelong surveillance is recommended
for prevention in AHCT survivors [9]. Important risk factors
for these cancers in MAC AHCT recipients include exposure
to higher dose of total body irradiation (TBI), younger age at
transplantation, use of HLA-mismatched donor, and chronic
graft-versus-host disease (GVHD) [1,3,6,7].
The introduction of reduced-intensity conditioning (RIC)
and nonmyeloablative conditioning (NMC) regimens over the
last decade now allows AHCT to be offered as a treatment
option for patients who are otherwise ineligible for trans-
plantation using MAC based on age, performance status, or
comorbidities [10-13]. AHCT using RIC/NMC regimens leads to
long-term engraftment, exhibits graft-versus-malignancy
effect, and results in signiﬁcantly lower early transplant-
related toxicity and mortality [14-18]. However, given the
recent introduction of these conditioning regimens, the
incidence and risk factors for late complications, including
second solid cancers, have not been adequately characterized.
In patients with cancer, less chemotherapy is associated
with a decreased probability of second malignancies [19-22].
It is therefore possible that RIC/NMC patients may have a
lower probability of developing second solid malignancies
compared with patients treated with MAC. On the other
hand, lower doses of TBI and chemotherapy may be more
carcinogenic than MAC regimens because cells may be
damaged but not eliminated. Also, RIC/NMC regimens are
typically used in older patients who have a higher baseline
cancer risk compared with MAC recipients who tend to be
younger in age. Recent data from a single-center study sug-
gest that the risk of second cancers after RIC/NMCmay not be
diminished compared with MAC [23]. Given the paucity of
studies characterizing second cancers in recipients of RIC/
NMC transplantation, additional data using large samples are
needed to better understand the impact of these potentially
devastating late effects.
Using data from an international transplant outcomes
registry, the Center for International Blood and Marrow
Transplant Research (CIBMTR), we describe the incidence
and risk factors for second solid cancers (excluding non-
melanoma skin cancers) after RIC/NMC AHCT for leukemia,myelodysplastic syndrome (MDS), and lymphoma. We also
compare the risks of second solid cancers after RIC/NMC
AHCT with general population control subjects. Finally, we
compare the risks of solid cancers after RIC/NMC and MAC
transplantation in a subgroup of patients with the same age
at transplantation (40 to 60 years).
METHODS
Data Source
The CIBMTR is a voluntary working group of more than 450 trans-
plantation centers worldwide that contribute detailed data on HCTs to a
Statistical Center at the Medical College of Wisconsin in Milwaukee and the
National Marrow Donor Program (NMDP) in Minneapolis. Participating
centers are required to report all transplants consecutively; compliance is
monitored by on-site audits. Patients are followed longitudinally. Comput-
erized checks for discrepancies, physicians’ review of submitted data, and
on-site audits of participating centers ensure data quality. Data are collected
before transplant, 100 days, and 6 months after transplant and annually
thereafter or until death. Among other data, all centers contribute data on
the development of a new malignancy and causes of death. Observational
studies conducted by the CIBMTR are performed under guidance of the
Institutional Review Board of the NMDP and are in compliance with all
applicable federal regulations pertaining to the protection of human
research participants.
Patients
The study included all patients receiving AHCT for acute myeloid leu-
kemia, acute lymphoblastic leukemia, chronic myeloid leukemia, MDS, and
lymphoma between 1995 and 2006 that were reported to the CIBMTR. We
limited our cohort to recipients of peripheral blood stemcell or bonemarrow
grafts from related or unrelated donors; umbilical cord blood transplant
recipients were excluded. Also excluded were patients who had received
syngeneic transplants. To avoid bias from inclusion of teamswith incomplete
follow-up and, consequently incomplete ascertainment of events in the late
post-transplant period, we excluded patients from centers with complete-
ness index of follow-up of <80% at 5 years post-transplantation (1179
patients from 68 centers) [24].
Study Deﬁnitions and Objectives
Conditioning regimens were deﬁned as MAC, RIC, and NMC using pre-
viously deﬁned guidelines [25]. Standard deﬁnitions were used for assigning
disease status (early, intermediate, or advanced) for patients with acute
myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leuke-
mia, and MDS [26]. The NMDP classiﬁcation of HLA-matching status was
used for unrelated donor AHCT recipients (well matched, partially matched,
or mismatched) [27]. Patients with leukemia/MDS and lymphoma were
analyzed separately given the differences in their pretransplant and trans-
plant treatment exposures. The CIBMTR routinely collects data on the
occurrence of secondary cancers after AHCT. For this study, when necessary,
pathology and physician reports of second cancers were requested from the
transplant centers and reviewed centrally at the CIBMTR and tumors
reclassiﬁed [28].
Statistical Analyses
For comparing groups, we used the chi-square or Fisher’s test (as
applicable) for categorical variables and Wilcoxon 2-sample test for
continuous variables. The cumulative incidence of solid cancers was esti-
mated taking into account the competing risk of death among patients who
Table 1
Characteristics of Adult Patients Receiving RIC/NMC AHCT for AML, ALL, CML, MDS, and Lymphoma between 1995 and 2006 and Reported to the CIBMTR
Characteristics Leukemia Cohort Lymphoma Cohort All Patients
Number of patients 2833 1436 4269
Number of centers 196 148 206
Median age at transplant, yr (range) 54 (<1-79) 49 (8-75) 53 (<1-79)
Age at transplant, yr
<20 198 (7) 47 (3) 245 (6)
20-39 456 (16) 374 (26) 830 (20)
40-59 1388 (49) 802 (56) 2190 (51)
60 791 (28) 213 (14) 1004 (23)
Patient gender
Male 1597 (56) 907 (63) 2504 (59)
Female 1236 (44) 529 (37) 1765 (41)
Karnofsky score before transplant
80 2309 (82) 1180 (82) 3489 (82)
<80 342 (12) 148 (10) 490 (11)
Missing 182 (6) 108 (8) 290 (7)
Region of teams
United States 2144 (76) 1295 (90) 3439 (81)
Canada 28 (1) 5 (<1) 33 (1)
Europe 399 (14) 79 (6) 478 (11)
Asia 137 (5) 7 (<1) 144 (3)
Australia/New Zealand 60 (2) 24 (2) 84 (2)
Middle East/Africa 27 (1) 20 (1) 47 (1)
Central/South America 38 (1) 6 (<1) 44 (1)
Disease
AML 1691 (60) d 1691 (40)
ALL 235 (8) d 235 (6)
CML 387 (14) d 387 (9)
MDS 520 (18) d 520 (12)
Lymphoma d 1436 (100) 1436 (34)
Disease risk before transplant*
Leukemia/MDS early 1195 (42) d 1195 (28)
Leukemia/MDS intermediate 613 (22) d 613 (14)
Leukemia/MDS advanced 989 (35) d 989 (23)
Missing 36 (1) d 36 (1)
Lymphoma d 1436 (100) 1436 (34)
Year of transplant
1995-1998 158 (6) 77 (6) 235 (5)
1999-2002 777 (27) 457 (31) 1224 (29)
2003-2006 1898 (67) 912 (64) 2810 (66)
Median interval from diagnosis to transplant, mo (range) 9 (<1-343) 33 (<1-413) 14 (<1-413)
Interval from diagnosis to transplant, mo
<6 899 (32) 29 (2) 928 (22)
6-11 816 (29) 142 (10) 958 (23)
12 1110 (39) 1256 (88) 2366 (56)
Missing 8 (<1) 9 (<1) 17 (<1)
Conditioning regimen
TBI þ Cy þ Flud  other 106 (4) 20 (1) 126 (3)
TBI þ Flud  other (no Cy) 570 (20) 246 (17) 816 (19)
Bu þ Flud  other 694 (24) 199 (14) 893 (21)
Mel þ Flud  other 631 (22) 309 (22) 940 (22)
Cy þ Flud  other 227 (8) 278 (19) 505 (12)
Other 605 (21) 384 (27) 989 (23)
TBI dose, cGy
No TBI 2019 (71) 1095 (76) 3114 (73)
400 625 (22) 290 (20) 915 (21)
>400 185 (7) 51 (4) 236 (6)
TBI dose missing 4 (<1) 0 4 (<1)
Donor
HLA-idential sibling 829 (29) 411 (29) 1240 (29)
Other related 99 (3) 38 (3) 137 (3)
Well-matched unrelated 1058 (37) 618 (43) 1676 (39)
Partially matched unrelated 448 (16) 276 (19) 724 (17)
Mismatched unrelated 145 (5) 62 (4) 207 (5)
Unknown degree of match, unrelated 254 (9) 31 (2) 285 (7)
Graft type
Bone marrow 625 (22) 351 (24) 976 (23)
Peripheral blood stem cells 2208 (78) 1085 (76) 3293 (77)
GVHD prophylaxis
Ex vivo T cell depletion  other 88 (3) 34 (1) 112 (3)
FK506 þ MMF  other 421 (15) 269 (19) 690 (16)
FK506 þ MTX  other (except MMF) 595 (21) 433 (30) 1028 (24)
FK506  others (except MTX, MMF) 196 (7) 83 (6) 279 (7)
CSA þ MMF  other (except FK506) 719 (25) 298 (21) 1017 (24)
(Continued on next page)
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Table 1
(continued)
Characteristics Leukemia Cohort Lymphoma Cohort All Patients
CSA þ MTX  other (except FK506, MMF) 461 (16) 173 (12) 634 (15)
CSA  other (except FK506, MTX, MMF) 147 (9) 108 (8) 355 (9)
Other GVHD prophylaxis 91 (3) 22 (2) 113 (3)
Missing 15 (1) 16 (1) 31 (1)
Subsequent transplant or DLI 594 (21) 497 (35) 1091 (26)
Prior autologous transplant 245 (9) 536 (37) 781 (18)
Median follow-up of survivors, mo (range) 72 (2-188) 72 (1-169) 72 (1-188)
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; Cy, cyclophosphamide; Flud, ﬂudarabine; Bu,
busulfan; Mel, melphalan; FK506, tacrolimus; MMF, mycophenolate mofetil; MTX, methotrexate; CSA, cyclosporine; DLI, donor lymphocyte infusion.
* Disease risk classiﬁcation: Early indicates AML/ALL in ﬁrst complete remission, CML in ﬁrst chronic phase, MDS refractory anemia, MDS refractory anemia
with ringed sideroblasts, unspeciﬁed MDS with <5% marrow blasts; intermediate, AML/ALL in second or greater complete remission, CML in second or greater
chronic phase, CML in accelerated phase; advanced, AML/ALL in primary induction failure or relapse, CML in blast phase, MDS refractory anemia with excess
blasts, MDS refractory anemia with excess blasts in transformation, unspeciﬁed MDS with 5% marrow blasts, chronic myelomonocytic leukemia.
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analyses were used to evaluate risk factors for cancers after RIC/NMC [29].
Risk factors considered included age at HCT, gender, Karnofsky performance
score at transplant, diagnosis/disease status, time from diagnosis to HCT, TBI
dose, donor/graft source, history of prior autologous transplant, GVHD
prophylaxis regimen, year of HCT, and occurrence of acute (grades II to IV) or
chronic GVHD.
The risk of cancer in patients receiving RIC/NMC regimens was
compared with that of the general population using methods described in
previous CIBMTR studies [1,5,6]. Brieﬂy, for each transplant recipient, the
number of person-years at risk was calculated from the date of trans-
plantation until date of last contact, death, or diagnosis of new cancer,
whichever occurred ﬁrst. Incidence rates for all invasive cancers in the
general population were obtained from selected registries in the United
States, England andWales, Europe, and Asia [28,30]. Age-, gender-, race- (for
United States), calendar yeare, and region-speciﬁc incidence rates for all
invasive solid cancers combined and for cancers of speciﬁc anatomical sites
were applied to the appropriate person-years at risk to compute the ex-
pected numbers of cancers. Observed-to-expected ratios, also called stan-
dardized incidence ratios (SIRs), were calculated, and the exact Poisson
distribution was used to calculate 95% conﬁdence intervals (CIs) [31].
For our second objective, we compared the risks of developing second
solid cancers in recipients of RIC/NMC and MAC regimens. We limited this
analysis to recipients who were ages 40 to 60 years at the time of trans-
plantation to compare cancer risks between the 2 conditioning regimens in
a relatively homogenous subgroup of patients. Furthermore, this age range
represented the largest group of RIC/NMC recipients. Cox proportional
hazards regression analyses were performed to evaluate the association of
conditioning regimen intensity with solid cancer risk [29]. In addition to the
main effect of conditioning intensity, variables considered were the same as
the ones included in the RIC/NMC risk factor analyses (see above). We also
compared the risk of cancer in this subgroup of patients with that of the
general population using the methods described above. Given the relatively
shorter follow-up for RIC/NMC recipients compared with MAC recipients,
this analysis was restricted to 10 years of follow-up.
All P values are 2-sided. All analyses were carried out using SAS statis-
tical software (SAS Institute Inc., Cary, NC).RESULTS
Patient and Transplant Characteristics of RIC/NMC
Recipients
A total of 4269 RIC/NMC recipients were included in our
analysis (2833 with leukemia/MDS, 1436 with lymphoma)
and represented 11,620 person-years of follow-up (Table 1).
The median age of the cohort at the time of AHCT was
53 years. Most patients had received their transplant in the
United States. Only 27% of patients received a TBI-based
conditioning regimen. An unrelated donor was used in 68%
of cases. The median follow-up for the whole cohort was
72 months (range, 1 to 188). There were some notable but
expected differences in the leukemia/MDS and lymphoma
cohorts. A greater proportion of lymphoma patients had
received a prior autologous transplant (37% versus 9%) and
their time from diagnosis to AHCT was longer (median33 months versus 9 months). The cumulative incidence of
acute grades II to IV GVHD at 100 days was 34% (95% CI, 32%
to 36%) in patients with leukemia/MDS and 33% (95% CI, 30%
to 36%) in patients with lymphoma. The 2-year cumulative
incidence of chronic GVHD was 43% (95% CI, 41% to 45%) and
49% (95% CI, 46% to 51%), respectively. The follow-up
completeness index for the entire cohort was 94% at
5 years and 83% at 10 years after transplantation.Cumulative Incidence and Risk Factors for Second Solid
Cancers in RIC/NMC Recipients
The cumulative incidence of second solid cancers for the
entire cohort was .54 (95% CI, .34 to .79) at 1 year, 1.69 (95%
CI, 1.32 to 2.12) at 5 years, and 3.35 (95% CI, 2.46 to 4.38) at
10 years after transplantation (Figure 1). Among patients
with leukemia/MDS, the cumulative incidence probabilities
at the 3 time points were .57 (95% CI, .32 to .88), 1.71 (95% CI,
1.26 to 2.24), and 3.61 (95% CI, 2.40 to 5.06), respectively.
Among lymphoma patients, 1-, 5-, and 10-year cumulative
incidences of second solid cancers were .49 (95% CI, .20 to
.92), 1.65 (95% CI, 1.04 to 2.41), and 2.98 (95% CI, 1.78 to 4.47),
respectively. In Cox regression analyses, age at AHCT was the
only risk factor independently associated with solid cancers
(hazard ratio [HR] 3.10 [95% CI, 1.89 to 5.07] for age>50 years
versus 50 years, P < .001).Cancer Risks of RIC/NMC Recipients Compared with the
General Population
Table 2 depicts the SIRs (or observed/expected ratios) for
second solid cancers in RIC/NMC recipients compared with
age- and gender-matched general population control sub-
jects. We observed no increase in the overall risk of second
solid cancers in patients receiving RIC/NMC AHCT for leu-
kemia/MDS (SIR .99, P¼ 1.00) or lymphoma (SIR .92, P¼ .75).
Increased risks compared with the general population
were seen for some speciﬁc solid cancer sites. Among leu-
kemia/MDS patients, these included cancers of the lip (SIR
14.28, P ¼ .02), tonsil (SIR 8.66, P ¼ .05), oropharynx (SIR
46.70, P< .01), bone (SIR 23.53, P< .01), soft tissue (SIR 12.92,
P < .01), and vulva (SIR 18.55, P ¼ .01). A reduced risk was
noted for breast cancer (SIR .25, P ¼ .03). Among patients
who had received a transplant for lymphoma, increased risks
were observed for cancers of the oropharynx (SIR 67.35,
P < .01). The risks for melanoma of the skin were higher in
control subjects than for patients with both leukemia (SIR
3.04, P ¼ .02) and lymphoma (SIR 3.52, P ¼ .03).
Figure 1. Cumulative incidence of second solid cancers (excluding non-
melanoma skin cancers) among patients receiving RIC/NMC regimens for
leukemia/MDS and lymphoma.
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NMC and MAC Regimens
Table 3 shows the characteristics of patients ages 40 to
60 years at AHCT who were included in the analysis
comparing cancer risks between RIC/NMC and MAC re-
cipients (leukemia/MDS: RIC/NMC ¼ 1355 and MAC ¼ 5728
patients; lymphoma: RIC/NMC ¼ 783 and MAC ¼ 700 pa-
tients). Among leukemia/MDS patients, 17,979 person-years
of follow-up was available for MAC recipients versus 3544
person-years for RIC/NMC recipients. The follow-up available
for lymphoma patients was 1914 person-years and 2552
person-years, respectively. The patients in the MAC cohort
were younger than the RIC/NMC cohort. A greater proportion
of RIC/NMC recipients had received AHCT more recently,
received a regimen that did not contain TBI, and had pe-
ripheral blood stem cells as a graft source. They were also
more likely to have received a prior autologous transplant.
Among leukemia/MDS patients, the cumulative incidence ofTable 2
Standardized Incidence (Observed/Expected) Ratios for Second Solid Cancers (Exc
with the General Population
Cancer Site Leukemia/MDS Cohort
Cases SIR 95% CI
Lip 2 14.28 1.73-51.57
Tongue 1 2.48 .06-13.80
Mouth 1 2.89 .07-16.08
Tonsil 2 8.66 1.05-31.27
Oropharynx 3 46.70 9.63-136.47
Esophagus 1 1.41 .04-7.87
Small intestine 1 4.84 .12-26.97
Colon 1 .26 .01-1.42
Rectum 1 .48 .01-2.66
Liver 2 2.70 .33-9.76
Pancreas 2 1.60 .19-5.79
Larynx 1 1.47 .04-8.20
Lung 8 .91 .39-1.79
Bone 2 23.53 2.85-85.01
Skin melanoma 7 3.04 1.22-6.27
Soft tissue 4 12.92 3.52-33.08
Breast 2 .25 .03-.91
Vulva 2 18.55 2.25-67.02
Cervix uteri 1 2.14 .05-11.93
Corpus uteri 1 .63 .02-3.52
Prostate 8 .66 .29-1.31
Testis 1 5.38 .14-29.99
Kidney 4 2.52 .69-6.45
Bladder 1 .37 .01-2.05
Thyroid 1 1.37 .04-7.64
All sites 58 .99 .75-1.28acute grades II to IV GVHD at 100 days was 42% (95% CI, 41%
to 43%) and that of chronic GVHD at 2 years was 43% (95% CI,
42% to 45%). Among patients with lymphoma, the corre-
sponding cumulative incidence estimates were 38% (95% CI,
35% to 40%) and 43% (95% CI, 40% to 45%), respectively.
The cumulative incidence of second cancers in the RIC/
NMC and MAC cohorts is shown in Figure 2. Among patients
with leukemia/MDS, the cumulative incidence of second
solid cancers at 10 years post-transplantationwas 3.03% (95%
CI, 2.52% to 3.57%) among MAC recipients and 4.29% (95% CI,
2.43% to 6.65%) among RIC/NMC recipients (P ¼ .25). The 10-
year incidences of second solid cancers among lymphoma
patients receiving MAC and RIC/NMC regimens were 3.95%
(95% CI, 2.47% to 5.76%) and 3.05% (95% CI, 1.50% to 5.13%),
respectively (P ¼ .48).
In multivariable analyses for leukemia/MDS, after
adjusting for patient, disease, and transplant variables, we
observed no signiﬁcant difference in the risks for second
solid cancers after adjusting for patient and disease charac-
teristics (HR .98 [95% CI, .64 to 1.45] for RIC/NMC versus MAC
regimens, P ¼ .905). After adjusting for other signiﬁcant
covariates, second solid cancer risks were lower in recipients
of RIC/NMC regimens with lymphoma, although this differ-
ence was only marginally signiﬁcant (HR .51 [95% CI, .26 to
.99] for RIC/NMC versus MAC regimens, P ¼ .047).
Table 4 demonstrates the results of the analysis of the
risks of second solid cancers among MAC and RIC/NMC
recipients ages 40 to 60 years compared with general pop-
ulation control subjects. In contrast to MAC regimens, the
RIC/NMC regimens are relatively newer, and patient follow-
up is comparatively shorter; hence, we restricted these
analysis to 10 years post-transplant. Patients with leukemia/
MDS and lymphoma who had received MAC regimens had a
signiﬁcantly higher risks of solid cancers compared with the
age-, gender-, and region-matched general population (SIR
1.46, P < .01 and SIR 2.35, P < .01, respectively). However,luding Nonmelanoma Skin Cancers) among RIC/NMC Recipients Compared
Lymphoma Cohort
P Cases SIR 95% CI P
.02 0 .00 d d
.66 1 4.17 .11-23.25 .42
.59 0 .00 d d
.05 0 .00 d d
<.01 2 67.35 8.16-243.30 <.01
1.00 0 .00 d d
.37 0 .00 d d
.19 2 1.09 .13-3.92 1.00
.76 1 .98 .03-5.47 1.00
.34 2 5.96 .72-21.54 .09
.71 1 1.70 .04-9.46 .89
.99 0 .00 d d
.96 4 .96 .26-2.44 1.00
<.01 0 .00 d d
.02 5 3.52 1.14-8.22 .03
<.01 0 .00 d d
.03 3 .82 .17-2.39 1.00
.01 0 .00 d d
.75 0 .00 d d
1.00 1 1.44 .04-8.05 .99
.30 5 .80 .26-1.86 .80
.34 0 .00 d d
.15 0 .00 d d
.49 0 .00 d d
1.00 1 2.22 .06-12.39 .72
1.00 27 .92 .61-1.34 .75
Table 3
Characteristics of Patients Ages 40 to 60 Years Included in the Analysis Comparing Risks of Second Solid Cancers among RIC/NMC and MAC Regimens
Characteristics Leukemia/MDS Lymphoma
MAC Regimens RIC/NMC
Regimens
P MAC Regimens RIC/NMC
Regimens
P
Number of patients 5728 1355 700 783
Age at transplant, yr <.001 <.001
40-49 3581 (62) 407 (30) 423 (60) 345 (44)
50-60 2147 (38) 948 (70) 277 (40) 438 (56)
Male gender 3071 (54) 732 (54) .79 467 (67) 490 (63) .10
Karnofsky score before transplant  80 4844 (85) 1092 (81) .001 588 (84) 640 (82) .02
Disease risk before transplant .02
Early 2782 (49) 597 (44) d d
Intermediate 1114 (19) 274 (20) d d
Advanced 1788 (31) 470 (35) d d
Unknown 44 (1) 14 (1) d d
Year of transplant <.001 <.001
1995-1998 2098 (37) 66 (5) 222 (32) 40 (5)
1999-2002 1689 (29) 376 (28) 254 (36) 259 (33)
2003-2006 1941 (34) 913 (67) 224 (32) 484 (62)
Median interval from diagnosis to transplant, mo (range) 8 (<1-338) 9 (<1-302) .02 20 (2-540) 36 (4-413) <.001
Conditioning regimen <.001 <.001
Bu þ Cy  other 2104 (37) 0 157 (22) 0
TBI þ Cy  other 2782 (49) 0 425 (61) 0
TBI þ Flud  other (no Cy) 0 279 (21) 0 139 (18)
Bu þ Flud  other 0 334 (25) 0 93 (12)
Mel þ Flud  other 0 308 (23) 0 163 (21)
Cy þ Flud  other 0 111 (8) 0 147 (19)
Other 842 (15) 323 (24) 118 (17) 241 (30)
TBI dose, cGy <.001 <.001
No TBI 2612 (46) 960 (71) 233 (33) 589 (75)
400 19 (<1) 314 (23) 0 172 (22)
401-800 154 (3) 80 (6) 30 (5) 22 (3)
801-1200 1705 (30) 0 329 (47) 0
>1200 1235 (22) 0 108 (15) 0
TBI dose missing 3 (<1) 1 (<1) 0 0
Donor* <.001 <.001
HLA-identical sibling 2318 (40) 421 (31) 415 (59) 271 (35)
Unrelated 3410 (60) 934 (69) 285 (41) 512 (65)
Graft type <.001 <.001
Bone marrow 3189 (56) 275 (20) 287 (41) 177 (23)
Peripheral blood stem cells 2539 (44) 1080 (80) 413 (59) 606 (77)
GVHD prophylaxis <.001 <.001
Ex vivo T cell depletion  other 497 (9) 37 (2) 98 (14) 17 (2)
FK506 þ MMF  other 229 (4) 221 (16) 41 (6) 139 (18)
FK506 þ MTX  other (except MMF) 1367 (24) 270 (20) 161 (23) 230 (29)
FK506  others (except MTX, MMF) 194 (4) 96 (7) 43 (7) 41 (5)
CSA þ MMF  other (except FK506) 81 (1) 352 (26) 10 (1) 179 (23)
CSA þ MTX  other (except FK506, MMF) 2908 (51) 226 (17) 262 (37) 97 (12)
CSA  other (except FK506, MTX, MMF) 266 (5) 114 (8) 52 (8) 59 (8)
Other GVHD prophylaxis 131 (2) 32 (2) 26 (4) 11 (2)
Missing 52 (1) 7 (1) 7 (1) 10 (1)
Subsequent transplant or DLI 541 (9) 285 (21) <.001 65 (9) 242 (31) <.001
Prior autologous transplant 117 (2) 130 (10) <.001 62 (9) 241 (31) <.001
Median follow-up of survivors, mo (range) 88 (2-204) 71 (2-163) 94 (3-189) 73 (3-168)
* HLA-mismatched related donors were excluded from this analysis.
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risks were not higher for patients receiving RIC/NMC
regimens (leukemia/MDS: SIR 1.20, P ¼ .34; lymphoma: SIR
.92, P ¼ .85).
DISCUSSION
Our study is the most comprehensive analysis of second
solid cancers after RIC/NMC regimens to date. We present
important information to assist clinicians when counseling
patients about screening and prevention of second solid
cancers. We observed a continued increase in the cumulative
incidence of second solid cancers over time. Despite these
ﬁndings, the overall risk of solid cancers was comparable
with general population control subjects of the same age and
gender as the RIC/NMC recipients. In MAC recipients, second
solid cancer risks do not start increasing until 5 to 10 yearspost-transplantation and later [5,6,32,33]. Given their
relatively recent advent in clinical practice, there is a need to
continue research and conduct studies with even longer
follow-up in RIC/NMC recipients to better understand and
realize the true risk of second solid cancers.
In the subset of patients 40 to 60 years of age, we
observed no signiﬁcant difference in the cumulative inci-
dence of solid cancers in multivariable analyses among RIC/
NMC andMAC recipients with leukemia/MDS. The difference
was only marginally signiﬁcant among patients with lym-
phoma. When comparing the risks of solid cancers among
recipients of both regimens with the risks expected in the
general population of the same age and gender, only MAC
recipients had higher risks than the general population.
Because RIC/NMC regimens are a relatively new addition to
clinical practice, the follow-up of RIC/NMC recipients was
Figure 2. Cumulative incidence of second solid cancers (excluding non-
melanoma skin cancers) among patients ages 40 to 60 years for leukemia/MDS
and lymphoma treated with RIC/NMC and myeloablative conditioning,
respectively.
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number of RIC/NMC recipients and second cancer events
were much smaller than the MAC cohort. Hence, our study
does not provide any deﬁnitive conclusions about risks of
second solid cancers among RIC/NMC recipients relative to
patients receiving MAC regimens. Because it can take more
than a decade post-transplantation before second solid
cancers begin tomanifest, this comparative analysis between
MAC and RIC/NMC recipients needs to be repeated as longer
follow-up for the latter becomes available. At the same time,
albeit the limitation of shorter follow-up for RIC/NMC re-
cipients, the comparable risks for solid cancers between the
2 regimensmay have other explanations. RIC/NMC recipients
may have similar exposures to risk factors that increase solid
cancer risks, such as pretransplant therapies (or even more
exposure in RIC/NMC recipients, including autologous
transplantation), acute and chronic GVHD, and the use and
duration of post-AHCT immune suppression.Table 4
Standardized Incidence (Observed/Expected) Ratios Comparing Risks of
Second Solid Cancers (Excluding Nonmelanoma Skin Cancers) in MAC and
RIC/NMC Recipients Ages 40 to 60 Years with that of the General Population
Time Period Post-AHCT Regimen n Cases SIR (95% CI) P*
Leukemia/MDS cohort
<1 yr MAC 5676 24 1.53 (.98-2.28) .06
RIC/NMC 1348 8 1.36 (.58-2.67) .48
1-4 yr MAC 2734 56 1.31 (.99-1.70) .06
RIC/NMC 689 16 1.09 (.62-1.78) .79
5-9 yr MAC 1581 53 1.61 (1.21-2.11) <.01
RIC/NMC 333 8 1.32 (.57-2.60) .53
Overall until 10 yry MAC 5676 133 1.46 (1.22-1.73) <.01
RIC/NMC 1348 32 1.20 (.82-1.70) .34
Lymphoma cohort
<1 yr MAC 680 4 2.46 (.67-6.30) .17
RIC/NMC 775 3 .98 (.20-2.85) 1.00
1-4 yr MAC 274 13 2.95 (1.57-5.05) <.01
RIC/NMC 454 10 1.08 (.52-2.00) .88
5-9 yr MAC 161 6 1.59 (.58-3.47) .36
RIC/NMC 259 3 .58 (.12-1.70) .49
Overall until 10 yrz MAC 680 23 2.35 (1.49-3.52) <.01
RIC/NMC 775 16 .92 (.52-1.49) .85
* P value comparing SIR of solid cancers in transplant recipients to age-,
gender-, and region-speciﬁc general population.
y Person-years of follow-up was 16,611 years for MAC recipients and
3506 years for RIC/NMC recipients.
z Person-years of follow-up was 1722 years for MAC recipients and
2497 years for RIC/NMC recipients.Signiﬁcantly elevated SIRs were observed for cancers of
the oropharyngeal tract, bone and soft tissue, and mela-
noma of the skin. Higher risks than the general population
have also been reported at these sites in MAC recipients
[5-7]. Patients with leukemia/MDS had a lower risk of
breast cancer compared with the general population.
However, breast cancer was reported in only 2 patients, and
this observation has to be interpreted with caution.
Furthermore, this is in contrast to the high risks of breast
cancer seen in women who receive TBI containing MAC
regimens [8]. Breast cancer is the most common cancer in
women, and its incidence increases with age. The risks of
breast cancer after RIC/NMC AHCT may be lower than that
of MAC given the lack of exposure to high doses of TBI. At
the same time, as illustrated by previous publications, the
incidence of secondary breast cancer starts to rise about
1 decade after AHCT. Therefore, more patients and longer
follow-up are needed to clarify the risks of secondary breast
cancer after RIC/NMC regimens.
The data from our study have to be interpreted while
considering the general limitations of a retrospective anal-
ysis using registry data. Details of pretransplant chemo-
therapy and radiation therapy exposures were not available.
Although several thousands of patients were included, some
cancers are indeed rare, and larger studies are required to
provide a better understanding of the incidence and risks of
speciﬁc second cancers. Observation time was more than
10 years for some patients, but longer follow-up is still
needed to fully characterize the complete risks of second
cancers in RIC/NMC recipients, because the risk of second
cancers after AHCT continues to increase over time
[1-3,5,6,34,35]. The present analysis is not conclusive but
adds to our understanding of second cancer risks after AHCT.
Despite these limitations, our study is the largest and most
comprehensive analysis to date of second solid cancer risks
after RIC/NMC transplantation.
Our study demonstrates that the incidence of second
solid cancers after RIC/NMC AHCT continues to increase with
time. RIC/NMC recipients should receive screening for solid
cancers in a manner that is similar to what is recommended
for MAC recipients [9]. Clinicians taking care of long-term
survivors after RIC/NMC AHCT should be aware of the
increased risk of cancers of the lip, tonsil, oropharynx, bone,
soft tissue, and vulva and skin melanoma. Future studies
with larger number of patients who have been followed for a
longer period of time are needed to better understand the
incidence and risks for secondary solid cancer after trans-
plantation using RIC/NMC regimens.
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